Intrauterine Growth Restriction (IUGR) as a potential target for transamniotic stem cell therapy.

Autor: Labuz DF; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, United States of America., Whitlock AE; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, United States of America., Kycia I; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, United States of America., Zurakowski D; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, United States of America., Fauza DO; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, United States of America. Electronic address: dario.fauza@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of pediatric surgery [J Pediatr Surg] 2022 Jun; Vol. 57 (6), pp. 999-1003. Date of Electronic Publication: 2022 Feb 14.
DOI: 10.1016/j.jpedsurg.2022.01.062
Abstrakt: Background: We sought to determine whether intrauterine growth restriction (IUGR) could be a target for mesenchymal stem cell (MSC)-based transamniotic stem cell therapy (TRASCET).
Methods: Pregnant dams subjected to hypoxia (10.5% O 2 ) cycles had their fetuses divided into four groups: untreated (n = 24) and three groups receiving volume-matched intra-amniotic injections of either saline (sham; n = 16), or suspensions of luciferase-labeled, syngeneic amniotic fluid-derived MSCs that were either native (TRASCET-unprimed; n = 29), or primed by exposure to IFNγ and IL-1β (TRASCET-primed; n = 31). Normal fetuses served as additional controls (n = 22). Multiple analyses were performed at term.
Results: Compared to normal, fetal weights were significantly decreased in all hypoxia groups (p = 0.002 to <0.001), except for TRASCET-primed. Placental efficiency (fetal/placental weight) was significantly decreased in all hypoxia groups (p = 0.002 to <0.001), but normalized in both TRASCET groups. A significant increase in metrial expression of IFNγ in both the untreated and sham groups (p = 0.04 to 0.02) was reversed only in the TRASCET-primed group. Luciferase DNA was present in both TRASCET groups' placentas.
Conclusions: Transamniotic stem cell therapy with primed mesenchymal stem cells reverses some of the effects of intrauterine growth restriction in a rat model. Further study into this novel approach for the treatment of this disease is warranted.
Level of Evidence: N/A (Animal and Laboratory Study).
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: